Answers are grounded in this paper and cite their sources.
1,4-Butanediol (1,4-BDO), one of the most important platform diols, has been widely utilized as a comonomer to manufacture several million tons of polymers every year. Microbial synthesis of the non-natural 1,4-BDO is extremely challenging. Although several artificial routes have been proposed and applied in Escherichia coli, among them, the branching metabolic flux from α-ketoglutarate (α-KG) to the artificial route was considered the most thermodynamically efficient solution. Establishing a 1,4-BDO synthesis route in Yarrowia lipolytica, a native α-KG and succinate hyperproducer, should have high potential. A CoA-dependent 1,4-BDO synthesis route was introduced into Y. lipolytica, followed by the investigation of rate-limiting steps, optimization of the thiamine dosage, improvement of the precursor and cofactor availability, and deletion of the competition step. It was illustrated that 1,4-BDO synthesis was susceptible to metabolic throughput of the GABA-succinate shunt and NADPH availability. Also, there was a trade-off between cellular growth and 1,4-BDO synthesis. A combinational strategy, in which hereditary dynamic regulation of thiamine was incorporated into those positive metabolic modifications, was implemented, and 6217.1 mg·L –1 1,4-BDO was achieved under the batch fermentation model. This work also demonstrated the high potential and capacity for biosynthesis of non-nature chemicals from TCA intermediates in the yeast cells, and provided a novel clue to rebalance the metabolic flux between the heterologous pathway and central metabolism.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: